↓ Skip to main content

Preclinical discovery and development of maraviroc for the treatment of HIV

Overview of attention for article published in Expert Opinion on Drug Discovery, April 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
23 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Preclinical discovery and development of maraviroc for the treatment of HIV
Published in
Expert Opinion on Drug Discovery, April 2015
DOI 10.1517/17460441.2015.1041497
Pubmed ID
Authors

Nevena Veljkovic, Jelica Vucicevic, Sabrina Tassini, Sanja Glisic, Veljko Veljkovic, Marco Radi

Abstract

Maraviroc is a first-in-class antiretroviral (ARV) drug acting on a host cell target (CCR5), which blocks the entry of the HIV virus into the cell. Maraviroc is currently indicated for combination ARV treatment in adults infected only with CCR5-tropic HIV-1. Areas covered: This drug discovery case history focuses on the key studies that led to the discovery and approval of maraviroc, as well as on post-launch clinical reports. The article is based on the data reported in published preclinical and clinical studies, conference posters and on drug package data. Expert opinion: The profound understanding of HIV's entry mechanisms has provided a strong biological rationale for targeting the chemokine receptor CCR5. The CCR5-antagonist mariviroc, with its unique mode of action and excellent safety profile, is an important therapeutic option for HIV patients. In general, the authors believe that targeting host factors is a useful approach for combating new and re-emerging transmissible diseases, as well as pathogens that easily become resistant to common antiviral drugs. Maraviroc, offering a potent and safe cellular receptor-mediated pharmacological response to HIV, has paved the way for the development of a new generation of host-targeting antivirals.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 23 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 30%
Student > Master 6 26%
Student > Bachelor 2 9%
Student > Postgraduate 2 9%
Student > Ph. D. Student 2 9%
Other 3 13%
Unknown 1 4%
Readers by discipline Count As %
Chemistry 6 26%
Biochemistry, Genetics and Molecular Biology 6 26%
Medicine and Dentistry 3 13%
Immunology and Microbiology 2 9%
Agricultural and Biological Sciences 1 4%
Other 3 13%
Unknown 2 9%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 May 2015.
All research outputs
#11,896,103
of 13,417,652 outputs
Outputs from Expert Opinion on Drug Discovery
#613
of 768 outputs
Outputs of similar age
#193,230
of 234,172 outputs
Outputs of similar age from Expert Opinion on Drug Discovery
#24
of 26 outputs
Altmetric has tracked 13,417,652 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 768 research outputs from this source. They receive a mean Attention Score of 2.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 234,172 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.